SE0104423D0 - Pregnane steroids and their use in the treatment of CNS disorders - Google Patents
Pregnane steroids and their use in the treatment of CNS disordersInfo
- Publication number
- SE0104423D0 SE0104423D0 SE0104423A SE0104423A SE0104423D0 SE 0104423 D0 SE0104423 D0 SE 0104423D0 SE 0104423 A SE0104423 A SE 0104423A SE 0104423 A SE0104423 A SE 0104423A SE 0104423 D0 SE0104423 D0 SE 0104423D0
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- cns disorders
- steroid
- substances
- hydroxy
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title abstract 3
- -1 Pregnane steroids Chemical class 0.000 title abstract 2
- 239000000126 substance Substances 0.000 abstract 3
- 150000003431 steroids Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000852 hydrogen donor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
| CNB028262751A CN100518741C (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
| CA2468248A CA2468248C (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
| ES02793723T ES2394639T3 (es) | 2001-12-27 | 2002-12-20 | Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS |
| PCT/SE2002/002423 WO2003059357A1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
| CNA2009101459536A CN101601674A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
| DK02793723.4T DK1458399T3 (da) | 2001-12-27 | 2002-12-20 | Pregnansteroider til brug i behandlingen af CNS-sygdomme |
| US10/499,214 US7960367B2 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids and their use in the treatment of CNS disorders |
| AU2002359202A AU2002359202C1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
| JP2003559519A JP2005519893A (ja) | 2001-12-27 | 2002-12-20 | Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド |
| EP10183670.8A EP2275109B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
| EP02793723A EP1458399B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
| CNA2009101459540A CN101601675A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
| AU2009201951A AU2009201951A1 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
| AU2009201956A AU2009201956B2 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
| JP2009256620A JP5289281B2 (ja) | 2001-12-27 | 2009-11-10 | Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド |
| US12/986,937 US8119619B2 (en) | 2001-12-27 | 2011-01-07 | Pregnane steroids and their use in the treatment of CNS disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0104423D0 true SE0104423D0 (sv) | 2001-12-27 |
Family
ID=20286518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7960367B2 (enExample) |
| EP (2) | EP1458399B1 (enExample) |
| JP (2) | JP2005519893A (enExample) |
| CN (3) | CN100518741C (enExample) |
| AU (3) | AU2002359202C1 (enExample) |
| CA (1) | CA2468248C (enExample) |
| DK (1) | DK1458399T3 (enExample) |
| ES (1) | ES2394639T3 (enExample) |
| SE (1) | SE0104423D0 (enExample) |
| WO (1) | WO2003059357A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4914368B2 (ja) * | 2004-11-18 | 2012-04-11 | ウメクライン アーベー | Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用 |
| RU2413516C2 (ru) * | 2004-11-18 | 2011-03-10 | Умекрин Аб | Гамк-стероидные антагонисты и их применение в лечении нарушений цнс |
| PL2711371T3 (pl) | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| US20090269795A1 (en) * | 2007-03-09 | 2009-10-29 | The Research Foundation Of State University Of New York | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| WO2011087441A1 (en) | 2010-01-14 | 2011-07-21 | Umecrine Mood Ab | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| US10150793B2 (en) * | 2011-05-20 | 2018-12-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of CB1 receptor |
| HRP20170503T1 (hr) | 2012-11-28 | 2017-06-16 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | 3-(4'-supstituirani)-benzil-eter derivati pregnenolona |
| ME03351B (me) * | 2014-01-29 | 2019-10-20 | Umecrine Cognition Ab | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| RS67063B1 (sr) * | 2017-01-09 | 2025-08-29 | Relmada Therapeutics Inc | Injektabilne suspenzije |
| WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| AU2018218823B2 (en) | 2017-02-10 | 2022-12-22 | Relmada Therapeutics, Inc. | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
| RU2020130861A (ru) | 2018-04-05 | 2022-05-05 | Асарина Фарма Апс | Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| US20240383941A1 (en) | 2021-11-10 | 2024-11-21 | Umecrine Ab | 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5439900A (en) * | 1993-02-25 | 1995-08-08 | Bukusoglu; Cuneyt | Methods and compositions for providing analgesia and enhanced anesthesia |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| JP2001527552A (ja) | 1997-05-02 | 2001-12-25 | アメリカン・ホーム・プロダクツ・コーポレイション | プロゲスチンとして有用な５α−プレグナン−３β，１６α−ジオール−２０−オンの３−硫酸エステルの医薬上許容される塩およびＣＮＳ障害 |
| DK0981349T3 (da) * | 1997-05-02 | 2003-03-10 | Wyeth Corp | 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme |
| CA2289108A1 (en) | 1997-05-02 | 1998-11-12 | American Home Products Corporation | Salts of 5.alpha.-pregn-16-en-3.beta.-ol-20-one 3-sulphate ester with progestin activity |
| ATE307592T1 (de) * | 1998-03-11 | 2005-11-15 | Torbjoern Backstroem | Epiallopregnanolon zur behandlung von krankheiten des cns |
| WO2000021977A1 (en) | 1998-10-13 | 2000-04-20 | American Home Products Corporation | Pregnane glucuronides |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
-
2001
- 2001-12-27 SE SE0104423A patent/SE0104423D0/xx unknown
-
2002
- 2002-12-20 ES ES02793723T patent/ES2394639T3/es not_active Expired - Lifetime
- 2002-12-20 CN CNB028262751A patent/CN100518741C/zh not_active Expired - Fee Related
- 2002-12-20 CN CNA2009101459540A patent/CN101601675A/zh active Pending
- 2002-12-20 AU AU2002359202A patent/AU2002359202C1/en not_active Ceased
- 2002-12-20 JP JP2003559519A patent/JP2005519893A/ja active Pending
- 2002-12-20 EP EP02793723A patent/EP1458399B1/en not_active Expired - Lifetime
- 2002-12-20 DK DK02793723.4T patent/DK1458399T3/da active
- 2002-12-20 US US10/499,214 patent/US7960367B2/en not_active Expired - Fee Related
- 2002-12-20 WO PCT/SE2002/002423 patent/WO2003059357A1/en not_active Ceased
- 2002-12-20 CN CNA2009101459536A patent/CN101601674A/zh active Pending
- 2002-12-20 EP EP10183670.8A patent/EP2275109B1/en not_active Expired - Lifetime
- 2002-12-20 CA CA2468248A patent/CA2468248C/en not_active Expired - Fee Related
-
2009
- 2009-05-18 AU AU2009201951A patent/AU2009201951A1/en not_active Abandoned
- 2009-05-18 AU AU2009201956A patent/AU2009201956B2/en not_active Ceased
- 2009-11-10 JP JP2009256620A patent/JP5289281B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-07 US US12/986,937 patent/US8119619B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8119619B2 (en) | 2012-02-21 |
| AU2009201956A2 (en) | 2010-02-18 |
| JP5289281B2 (ja) | 2013-09-11 |
| JP2010065052A (ja) | 2010-03-25 |
| CA2468248C (en) | 2011-08-16 |
| EP2275109A2 (en) | 2011-01-19 |
| CA2468248A1 (en) | 2003-07-24 |
| EP2275109A3 (en) | 2011-10-12 |
| EP2275109B1 (en) | 2013-07-24 |
| CN101601674A (zh) | 2009-12-16 |
| ES2394639T3 (es) | 2013-02-04 |
| CN1607954A (zh) | 2005-04-20 |
| EP1458399A1 (en) | 2004-09-22 |
| EP1458399B1 (en) | 2012-08-08 |
| WO2003059357A1 (en) | 2003-07-24 |
| AU2009201956A1 (en) | 2009-06-11 |
| US7960367B2 (en) | 2011-06-14 |
| AU2002359202A1 (en) | 2003-07-30 |
| AU2002359202B2 (en) | 2009-02-19 |
| AU2002359202C1 (en) | 2011-03-31 |
| US20110098259A1 (en) | 2011-04-28 |
| CN101601675A (zh) | 2009-12-16 |
| AU2009201956B2 (en) | 2010-11-25 |
| AU2009201951A1 (en) | 2009-06-04 |
| DK1458399T3 (da) | 2012-11-12 |
| JP2005519893A (ja) | 2005-07-07 |
| US20050222099A1 (en) | 2005-10-06 |
| CN100518741C (zh) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0104423D0 (sv) | Pregnane steroids and their use in the treatment of CNS disorders | |
| NL300808I1 (enExample) | ||
| AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| TW200504078A (en) | Therapeutically active compounds and their use | |
| HK1047693A1 (zh) | 治疗全身性焦虑障碍的环苯扎林及其组合物 | |
| ID26781A (id) | Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer | |
| WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
| DK1056856T3 (da) | Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf | |
| AU3703900A (en) | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders | |
| WO2001026658A3 (en) | Topical nasal treatment using desloratadine | |
| BR0014312A (pt) | Combinação de loteprednol e anti-histaminas | |
| ZA200107689B (en) | 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| ATE400564T1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
| BG106226A (en) | A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders | |
| WO2003047507A3 (en) | Factor viii c2 domain variants | |
| ZA200505989B (en) | Use the steroids to treat ocular disorders | |
| AU2002363973A8 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
| EP1229973A4 (en) | SWING FOR THE DISABLED | |
| PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
| DE602004014020D1 (de) | Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol | |
| BR0010560A (pt) | 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados | |
| AU2092300A (en) | Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders | |
| ZA200405173B (en) | 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence. | |
| ITBO990629A0 (it) | Dispositivo per impianto vascolare nel trattamento percutaneo delle le sioni carotidee . |